Skip to main content
. Author manuscript; available in PMC: 2015 Aug 12.
Published in final edited form as: Mol Cancer Ther. 2015 Feb 23;14(3):769–778. doi: 10.1158/1535-7163.MCT-14-0926

Figure 3.

Figure 3

AR knockdown inhibits baseline and ligand-mediated proliferation and increases apoptosis in TNBC. A, Western blotting of TNBC cell lines infected with shRNAs targeting AR (shAR15, shAR17) compared with a nontargeting control (shNEG) on day 3. B, MTS assays of transduced TNBC cell lines. C, crystal violet assay of transduced SUM159PT shNEG or shAR15/shAR17 cells treated 1 week with vehicle control (Veh), enzalutamide (ENZ), and/or DHT. D, changes in apoptosis in AR knockdown cells measured with cleaved caspase reagent (Essen BioSciences) and normalized to cell count (apoptotic index) at 42 hours. Staurosporine (SSP) was used a positive control for apoptosis. *, P < 0.05; ***, P < 0.001 by ANOVA; error bars, SD.